<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02779699</url>
  </required_header>
  <id_info>
    <org_study_id>AL2846-I-0001</org_study_id>
    <nct_id>NCT02779699</nct_id>
  </id_info>
  <brief_title>A Study of AL2846 on Tolerance and Pharmacokinetics</brief_title>
  <official_title>Phase I Study of Tolerance and Pharmacokinetics of AL2846 in Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of AL2846,a C-met/Hepatocyte growth factor tyrosine kinase inhibitor,in patients with&#xD;
      advanced cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To study the pharmacokinetic characteristics of AL2846 in the human body; To recommend a&#xD;
      reasonable dose and indication for subsequent research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The type of dose-limiting toxicity(ies) (DLT[s]) of AL2846</measure>
    <time_frame>For 4 weeks for DLTs</time_frame>
    <description>Subjects within 28 days after treatment appear the following toxicity reaction relate to the drug ：II °or above of kidney damage，III °or above of non-hematological toxicity,IV°hematological toxicity ,Neutropenia associated with fever.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of AL2846 (in plasma)</measure>
    <time_frame>up to 28 Days (endpoint when the two consecutive time points of blood drug concentration &lt;150 DPM/mL)</time_frame>
    <description>In the study of single-dose, full PK profiles will be obtained at H0/H0.5/H1/H2/H4/H8/H11/H24/H34/H48/H58/H72/H96/H120/H168 (H means Hour). In the study of multiple-dose, full PK profiles will be obtained at D0/D1/D4/D7/D10/D13/D15/D18/D21/D24/D28 (D means Day).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) of AL2846</measure>
    <time_frame>48 weeks</time_frame>
    <description>The highest dose at which no more than 33% of the subjects experience a dose-limiting toxicity (DLT) during treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>each 56 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>Percentage of participants with OR based assessment of confirmed complete remission (CR) or confirmed partial remission (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>AL2846</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL2846 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL2846</intervention_name>
    <description>AL2846 p.o. qd</description>
    <arm_group_label>AL2846</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological documentation of Advanced solid tumors（especially Hepatocellular&#xD;
             Carcinoma and Lung Cancer ）,at least one measurable lesion (by RECIST1.1)&#xD;
&#xD;
          -  Lack of the standard treatment or treatment failure&#xD;
&#xD;
          -  18-65 years,ECOG PS:0-1,Life expectancy of more than 3 months&#xD;
&#xD;
          -  30 Days or more from the last cytotoxic therapy&#xD;
&#xD;
          -  Main organs function is normal&#xD;
&#xD;
          -  Women of childbearing potential should agree to use and utilize an adequate method of&#xD;
             contraception (such as intrauterine device，contraceptive and condom) throughout&#xD;
             treatment and for at least 6 months after study is stopped；the result of serum or&#xD;
             urine pregnancy test should be negative within 7 days prior to study enrollment，and&#xD;
             the patients required to be non-lactating；Man participants should agree to use and&#xD;
             utilize an adequate method of contraception throughout treatment and for at least 6&#xD;
             months after study is stopped&#xD;
&#xD;
          -  Patients should participate in the study voluntarily and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from other malignancies currently or ever, except for cured&#xD;
             cervical carcinoma in situ, non-melanoma skin cancers&#xD;
&#xD;
          -  Patients with factors that could affect oral medication (such as dysphagia，chronic&#xD;
             diarrhea, intestinal obstruction etc.)&#xD;
&#xD;
          -  Patients participated in other anticancer drug clinical trials within 4 weeks or&#xD;
             Patients participating in other clinical trials now&#xD;
&#xD;
          -  Blood pressure unable to be controlled ideally by one drug(systolic pressure≥140&#xD;
             mmHg，diastolic pressure≥90 mmHg); Patients with Grade 1 or higher myocardial ischemia,&#xD;
             myocardial infarction or malignant arrhythmias(including male QTc≥450ms,female&#xD;
             QTc≥470ms) and patients with Grade 1 or higher congestive heart failure (NYHA&#xD;
             Classification)&#xD;
&#xD;
          -  Urine protein ≥ ++，and 24-hour urinary protein excretion&gt;1.0 g confirmed&#xD;
&#xD;
          -  Patients with non-healing wounds or fractures&#xD;
&#xD;
          -  Patients with drug abuse history and unable to get rid of or Patients with mental&#xD;
             disorders&#xD;
&#xD;
          -  History of immunodeficiency&#xD;
&#xD;
          -  Patients with concomitant diseases which could seriously endanger their own safety or&#xD;
             could affect completion of the study according to investigators' judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuankai Shi, doctor</last_name>
    <email>syuankaipumc@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuankai Shi, doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 16, 2016</study_first_submitted>
  <study_first_submitted_qc>May 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2016</study_first_posted>
  <last_update_submitted>May 19, 2019</last_update_submitted>
  <last_update_submitted_qc>May 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

